Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp 140 trimer

Vaccine

Volumn 32, Issue 18, 2014, Pages 2109-2116

  Nkolola, Joseph P ^a   Cheung, Ann ^a   Perry, James R ^a   Carter, Darrick ^b   Reed, Steve ^b   Schuitemaker, Hanneke ^c   Pau, Maria Grazia ^c   Seaman, Michael S ^a   Chen, Bing ^d,e   Barouch, Dan H ^a,f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Adjuvants; Env; HIV 1

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; EMULSIGEN; GLUCOPYRANOSYL LIPID ADJUVANT EMUSLION; GLUCOPYRANOSYL LIPID ADJUVANT LIPOSOME; GLYCOPROTEIN GP 140; IMMUNOLOGICAL ADJUVANT; ISCOM; MATRIX M; PHOSPHORYL LIPID A; TREHALOSE DICORYNOMYCOLATE; UNCLASSIFIED DRUG; VIROSOME;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN STRUCTURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN C); HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SHAM PROCEDURE;

ADJUVANTS; ENV; HIV-1;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GUINEA PIGS; HIV ANTIBODIES; NEUTRALIZATION TESTS; PROTEIN STABILITY;

EID: 84896542519     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.001     Document Type: Article

References (34)

1. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., et al. A blueprint for HIV vaccine discovery. Cell Host & Microbe 2012, 12:396-407.
2. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
3. Srivastava I.K., Ulmer J.B., Barnett S.W. Role of neutralizing antibodies in protective immunity against HIV. Human Vaccines 2005, 1:45-60.
4. Pierson T.C., Doms R.W. HIV-1 entry and its inhibition. Current Topics in Microbiology and Immunology 2003, 281:1-27.
5. Nara P.L., Robey W.G., Pyle S.W., Hatch W.C., Dunlop N.M., Bess J.W., et al. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. Journal of Virology 1988, 62:2622-2628.
6. Berman P.W., Eastman D.J., Wilkes D.M., Nakamura G.R., Gregory T.J., Schwartz D., et al. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994, 8:591-601.
7. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Journal of Infectious Diseases 2005, 191:654-665.
8. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Journal of Infectious Diseases 2006, 194:1661-1671.
9. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007, 360:329-340.
10. Khayat R., Lee J.H., Julien J.P., Cupo A., Klasse P.J., Sanders R.W., et al. Structural characterization of cleaved, soluble human immunodeficiency virus type-1 envelope glycoprotein trimers. Journal of Virology 2013, 87(17):9865-9872.
11. Kovacs J.M., Nkolola J.P., Peng H., Cheung A., Perry J., Miller C.A., et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12111-12116.
12. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. Journal of Virology 2010, 84:3270-3279.
13. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., Liao H.X. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Research and Human Retroviruses 2005, 21:58-67.
14. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends in Immunology 2009, 30:23-32.
15. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
16. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine 2005, 11:S63-S68.
17. Lore K., Karlsson Hedestam G.B. Novel adjuvants for B cell immune responses. Current Opinion in HIV and AIDS 2009, 4:441-446.
18. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. Journal of Virology 2005, 79:10103-10107.
19. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods in Molecular Biology 2009, 485:395-405.
20. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. Journal of Virology 2002, 76:9002-9010.
21. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. Journal of Virology 2006, 80:1414-1426.
22. Buffa V., Klein K., Fischetti L., Shattock R.J. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS ONE 2012, 7:e50529.
23. Arias M.A., Van Roey G.A., Tregoning J.S., Moutaftsi M., Coler R.N., Windish H.P., et al. Glucopyranosyl Lipid Adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS ONE 2012, 7:e41144.
24. Lai R.P., Seaman M.S., Tonks P., Wegmann F., Seilly D.J., Frost S.D., et al. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS ONE 2012, 7:e35083.
25. Buglione-Corbett R., Pouliot K., Marty-Roix R., West K., Wang S., Lien E., et al. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS ONE 2013, 8:e74820.
26. Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., et al. Eleven years of Inflexal V - a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27:4381-4387.
27. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Current Opinion in Immunology 2009, 21:23-29.
28. Exley C., Siesjo P., Eriksson H. The immunobiology of aluminium adjuvants: how do they really work?. Trends in Immunology 2010, 31:103-109.
29. Lambert S.L., Yang C.F., Liu Z., Sweetwood R., Zhao J., Cheng L., et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PLoS ONE 2012, 7:e51618.
30. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011, 6:e16333.
31. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica acta 1999, 1489:107-116.
32. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
33. Lovgren Bengtsson K., Morein B., Osterhaus A.D. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Review of Vaccines 2011, 10:401-403.
34. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Review of Vaccines 2003, 2:219-229.